1.Hanahan D，Weinberg RA. Hallmarks of cancer：the next generation.Cell，2011，144（5）：646-674.

2.Chen DS，Mellman I.Oncology meets immunology：the cancer-immunity cycle.Immunity，2013，39（1）：1-10.

3.Ahmad M，Rees RC，Ali SA. Escape from immunotherapy：possible mechanisms that influence tumor regression/ progression.Cancer Immunol Immunother，2004，53（10）：844-854.

4.Yang L，Carbone DP.Tumor-host immune interactions and dendritic cell dysfunction.Adv Cancer Res，2004，92：13-27.

5.Konishi J，Yamazaki K，Azuma M，et al.B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res，2004，10（15）：5094-5100.

6.Einhorn LH，Bond WH，Hornback N，et al.Long-term results in combined-modality treatment of small cell carcinoma of the lung.Semin Oncol，1978，5（3）：309-313.

7.Schiller JH，Morgan-ihrig C，Levitt ML.Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer.Am J Clin Oncol，1995，18（1）：47-51.

8.Jansen RL，Slingerland R，Goey SH，et al.Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small cell lung cancer.J Immunother（1991），1992，12（1）：70-73.

9.Butts C，Socinski MA，Mitchell PL，et al.Tecemotide（L-BLP25） versus placebo after chemoradiotherapy for stageⅢ non-small-cell lung cancer（START）：a randomised，double-blind，phase 3 trial.Lancet Oncol，2014，15（1）：59-68.

10.Giaccone G，Bazhenova L，Nemunaitis J，et al. A phase Ⅲ study of belagenpumatucel-L，an allogeneic tumor cell vaccine，as maintenance therapy for non-small cell lung cancer. Eur J Cancer，2015，51（16）：2321-2329.

11.O’Day SJ，Hamid O，Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4（CTLA-4）：a novel strategy for the treatment of melanoma and other malignancies.Cancer，2007，110（12）：2614-2627.

12.Keir ME，Butte MJ，Freeman GJ，et al.PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol，2008，26（1）：677-704.

13.Nishimura H，Honjo T.PD-1：an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol，2001，22（5）：265-268.

14.Roth CG，Garner K，Eyck ST，et al.TIM3 expression by leukemic and non-leukemic myeloblasts. Cytometry B Clin Cytom，2013，84（3）：167-172.

15.Wada J，Kanwar YS.Identification and characterization of galectin-9，a novel beta-galactoside-binding mammalian lectin. J Biol Chem，1997，272（9）：6078-6086.

16.Sega EI，Leveson-Gower DB，Florek M，et al. Role of lymphocyte activation gene-3（lag-3） in conventional and regulatory T cell function in allogeneic transplantation. PLOS ONE，2014，9（1）：e86551.

17.Watanabe N，Gavrieli M，Sedy JR，et al.BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1.Nat Immunol，2003，4（7）：670-679.

18.Pasero C，Olive D.Interfering with coinhibitory molecules：BTLA/HVEM as new targets to enhance anti-tumor immunity.Immunol Lett，2013，151（1-2）：71-75.

19.Lee CF，Lai HL，Lee YC，et al. The A2A adenosine receptor is a dual coding gene：a novel mechanism of gene usage and signal transduction. J Biol Chem，2014，289（3）：1257-1270.

20.Sica GL，Choi IH，Zhu G，et al. B7-H4，a molecule of the B7 family，negatively regulates T cell immunity. Immunity，2003，18（6）：849-861.

21.Kohrt HE，Thielens A，Marabelle A，et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.Blood，2014，123（5）：678-686.

22.Farres MN，Sabry MK，Ahmed EE，et al. OX40 ligand：a potential costimulatory molecule in atopic asthma.J Asthma，2014，51（6）：573-577.

23.Shao Z，Schwarz H. CD137 ligand，a member of the tumor necrosis factor family，regulates immune responses via reverse signal transduction. J Leukoc Biol，2011，89（1）：21-29.

24.Chatzigeorgiou A，Lyberi M，Chatzilymperis G，et al. CD40/CD40L signaling and its implication in health and disease. Biofactors，2009，35（6）：474-483.

25.Viac J，Schmitt D，Claudy A. CD40 expression in epidermal tumors. Anticancer Res，1997，17（1B）：569-572.

26.Prasad KV，Ao Z，Yoon Y，et al. CD27，a member of the tumor necrosis factor receptor family，induces apoptosis and binds to Siva，a proapoptotic protein.Proc Natl Acad Sci USA，1997，94（12）：6346-6351.

27.Nocentini G，Ronchetti S，Cuzzocrea S，et al.GITR/GITRL：more than an effector T cell co-stimulatory system. Eur J Immunol，2007，37（5）：1165-1169.

28.Yoshinaga SK，Whoriskey JS，Khare SD，et al. T-cell co-stimulation through B7RP-1 and ICOS.Nature，1999，402（6763）：827-832.

29.Woerly G，Roger N，Loiseau S，et al. Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines（interleukin 2 and interferon gamma）：inhibition by immunoglobulin a complexes. J Exp Med，1999，190（4）：487-495.

30.Chambers CA，Kuhns MS，Egen JG，et al. CTLA-4-mediated inhibition in regulation of T cell responses：mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol，2001，19（1）：565-594.

31.Thompson CB，Allison JP. The emerging role of CTLA-4 as an immune attenuator.Immunity，1997，7（4）：445-450.

32.Waterhouse P，Penninger JM，Timms E，et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4.Science，1995，270（5238）：985-988.

33.Salvi S，Fontana V，Boccardo S，et al. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother，2012，61（9）：1463-1472.

34.Zheng H，Li Y，Wang X，et al. Expression and significance of gp96 and immune-related gene CTLA-4，CD8 in lung cancer tissues. Zhongguo Fei Ai Za Zhi，2010，13（8）：790-794.

35.Lynch TJ，Bondarenko I，Luft A，et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage ⅢB/Ⅳ non-small-cell lung cancer：results from a randomized，double-blind，multicenter phaseⅡ study. J Clin Oncol，2012，30（17）：2046-2054.

36.Zatloukal P，Heo DS，Park K，et al.Randomized phaseⅡ clinical trial comparing tremelimumab（CP-675，206）with best supportive care（BSC） following first-line platinum-based therapy in patients（pts） with advanced nonsmall cell lung cancer（NSCLC）. J Clin Oncol，2009，27（suppl；abstr 15S，8071）.

37.Ahmadzadeh M，Johnson LA，Heemskerk B，et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood，2009，114（8）：1537-1544.

38.Topalian SL，Hodi FS，Brahmer JR，et al.Safety，activity，and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med，2012，366（26）：2443-2454.

39.Brahmer J，Horn L，Antonia S，et al. Nivolumab（anti-PD-1；BMS-936558；ONO-4538） in patients with nonsmall cell lung cancer（NSCLC）：overall survival and long-term safety in a phase 1 trial. In：IASLC 15th World Conference on Lung Cancer，2013，Abstract MO18.03.

40.Antonia S，Grosso J，Horak C，et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with non-small cell lung cancer treated with nivolumab. In：IASLC 15th World Conference on Lung Cancer，2013.Abstract P2.11-035.

41.Spigel DR，Reckamp KL，Rizvi NA，et al. A phase Ⅲ study（CheckMate 017） of nivolumab（NIVO；antiprogrammed death-1 ［PD-1］） vs docetaxel（DOC） in previously treated advanced or metastatic squamous（SQ）cell non-small cell lung cancer（NSCLC）. In：American society of clinical oncology，2015.Abstract 8009.

42.Paz-Ares L，Horn L，Borghaei H，et al. Phase Ⅲ，randomized trial（CheckMate 057） of nivolumab（NIVO） versus docetaxel（DOC） in advanced non-squamous cell（non-SQ） non-small cell lung cancer（NSCLC）. In：American society of clinical oncology，2015.Abstract LBA109.

43.Hamid O，Robert C，Daud A，et al. Safety and tumor responses with lambrolizumab（anti-PD-1） in melanoma. N Engl J Med，2013，369（2）：134-144.

44.Garon E，Balmanoukian A，Hamid O，et al. Preliminary clinical safety and activity of MK-3475 mono-therapy for the treatment of previously treated patients with non-small cell lung cancer. In：IASLC 15th World Conference on Lung Cancer，2013.Abstract MO18.02.

45.Garon EB，Rizvi NA，Hui R，et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med，2015，372（21）：2018-2028.

46.Dong H，Strome SE，Salomao DR，et al. Tumor-associated B7-H1 promotes T-cell apoptosis：a potential mechanism of immune evasion. Nat Med，2002，8（8）：793-800.

47.Yang CY，Lin MW，Chang YL，et al. Programmed cell death-ligand 1 expression in surgically resected stageⅠpulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer，2014，50（7）：1361-1369.

48.Velcheti V，Schalper KA，Carvajal DE，et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest，2014，94（1）：107-116.

49.Chen YY，Wang LB，Zhu HL，et al. Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients. Chin Med Sci J，2013，28（3）：147-151.

50.Chen YB，Mu CY，Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer：a 5-year-follow-up study. Tumor，2012，98（6）：751-755.

51.Boland JM，Kwon ED，Harrington SM，et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer，2013，14（2）：157-163.

52.Mu CY，Huang JA，Chen Y，et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol，2011，28（3）：682-688.

53.Konishi J，Yamazaki K，Azuma M，et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res，2004，10（15）：5094-5100.

54.Velcheti V，Rimm DL，Schalper KA.Sarcomatoid lung carcinomas show high levels of programmed death ligand-1（PD-L1）.J Thorac Oncol，2013，8（6）：803-805.

55.Brahmer JR，Tykodi SS，Chow LQ，et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med，2012，366（26）：2455-2465.

56.Soria J，Cruz C，Bahleda R，et al. Clinical activity，safety and biomarkers of PD-L1 blockade in non-small cell lung cancer（NSCLC）：additional analyses from a clinical study ofthe engineered antibody MPDL3280A（anti-PDL1）. In：European Cancer Congress，2013.Abstract 3408.

57.Khleif S，Lutzky J，Segal N，et al. MEDI4736，an anti-PD-L1 antibody with modified Fc domain：preclinical evaluation and early clinical results from a phase 1 study in patients with advanced solid tumors. In：European Cancer Congress，2013.Abstract 802.

58.Hodi FS，Butler M，Oble DA，et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA，2008，105（8）：3005-3010.

59.Curran MA，Montalvo W，Yagita H，et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.Proc Natl Acad Sci USA，2010，107（9）：4275-4280.

60.Hanahan D，Weinberg RA. Hallmarks of cancer：the next generation. Cell，2011，144（5）：646-674.

61.Chen DS，Mellman I. Oncology meets immunology：the cancer-immunity cycle. Immunity，2013，39（1）：1-10.

62.Ahmad M，Rees RC，Ali SA. Escape from immunotherapy：possible mechanisms that influence tumor regression/ progression. Cancer Immunol Immunother，2004，53（10）：844-854.

63.Yang L，Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res，2004，92：13-27.

64.Patnaik A，Socinski MA，Gubens MA，et al. Phase 1 study of pembrolizumab（pembro；MK-3475） plus ipilimumab（IPI） as second-line therapy for advanced non-small cell lung cancer（NSCLC）：KEYNOTE-021 cohort D. In：American society of clinical oncology，2015，Abstract 8011.